test

test ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoingtest ongoing

The study is aimed to evaluate, through a pragmatic trial, safety and efficacy of switching from the adalimumab and etanercept originator molecules versus their biosimilar competitors and vice-versa in children with JIA in clinical remission on anti-TNF medication.

The comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS trial (STARS) is a new interventional trial aiming to investigate whether an early aggressive therapeutic intervention in children with JIA, based on the initial start of synthetic and biologic DMARDs (Step-down strategy), is superior to an approach based on treatment escalation conducted following the treat-to-target principle (Step-up strategy).

An open-ended, phase IV post marketing surveillance study conducted among members of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and of the Paediatric Rheumatology International Trials Organisation (PRINTO) to identify patients with polyarticular course JIA who had received CSA during the course of their disease.

SHARE Project

The “Single Hub and Access point for paediatric Rheumatology in Europe” (SHARE) is a European project whose main objective is to improve the quality of care of patients suffering from Paediatric Rheumatic Diseases.

ABIRISK

PRINTO collected samples of children with JIA newly treated with adalimumab, etanercept or tocilizumab within the project ABIRISK, funded by IMI, which has the aim to investigate antidrug antibody formation in the treatment with biopharmaceuticals

EPOCA

PRINTO is cross-culturally adapting and validating a questionnaire which aims to enable a multidimensional assessment of the disease status and quality of life of children with JIA: the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

PharmaChild

PRINTO and PRES are conducting a pharmacovigilance project which aims at observing children with JIA for 3-10 years undergoing treatment with MTX or biologic agents in order to collect moderate, severe or serious adverse events occurred.

Juvenile dermatomyositis trial

PRINTO designed the present study as a 5-year phase III single-blind, randomized clinical trial in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate, versus PDN plus Cyclosporine A…

Eurofever Project

The PReS Autoinflammatory Diseases’ Working Group, in collaboration with PRINTO, set up a a web-based international registry for Autoinflammatory diseases.

Liaisons with pharmaceutical companies

PRINTO is working with pharmaceutical companies as advisor for trials planning, centre selection, data collection, data analysis and interpretation…

TEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST RECRUITINGTEST

TEST PAST TEST PAST TEST PAST TEST PAST TEST PAST TEST PAST TEST PAST TEST PAST TEST PAST

Questo è un semplice test.

MAS Consensus Criteria

The project is aimed to develop' a new set of classification criteria for macrophage activation syndrome (MAS) occurring in the context of systemic juvenile idiopathic arthritis.

PRES/PRINTO/EULAR vasculitides registry

The PReS Vasculitis Working Group, in collaboration with PRINTO and with the EULAR support designed the present registry to validate the recently developed “EULAR/PreS endorsed criteria for the classification of childhood vasculitides”.

Genomics and Pediatric Rheumatic Diseases survey

PRINTO designed the present survey to investigate if the PRINTO centres have families with paediatric rheumatic diseases where more cases of the same disease (e.g. JIA or JSLE or JDM etc) are present among brothers and/or sisters (affected sib pairs)

MTX withdrawal in juvenile idiopathic arthritis

PRINTO designed the present trial to determine if the time to discontinuation of Methotrexate (6 versus 12 months) in Juvenile Idiopathic Arthritis, after the patient has reached clinical remission, influence the time to relapse…

Training in paediatric rheumatology for Latin America physicians

PRINTO set up a scientific and technical collaborative network of first level research training in Paediatric Rheumatology, to support mainly Latin America and European physicians

A web site for families of children with paediatric rheumatic diseases (www.pediatric-rheumatology.printo.it) and health professionals

PRINTO set up a project to define to set up a web site, translated in all the language of the countries belonging to PRINTO with up-to-date consensus information on paediatric rheumatic diseases; the map of the centres…

Disease activity and damage core sets and definition of improvement for juvenile systemic lupus erythematosus and juvenile dermatomyositis

PRINTO set up a project to define core sets of outcome measures for disease activity and disease damage assessment and definitions of improvement, to be used in clinical trials and outcome assessment studies in children with JSLE and JDM…

The quality of life project

PRINTO was able to cross culturally adapt and validate 2 childhood questionnaires for the health related quality of life evaluation: the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)…

The methotrexate trial in intermediate versus higher dose in juvenile idiopathic arthritis

PRINTO set up a randomized trial to compare intermediate versus higher doses of MTX in children with JIA. The trial was built on the current "standard of care"…

Core set of outcome measures and definition of improvement for juvenile arthritis

PRINTO first achieved goals was to define a core set of outcome measures and a definition of improvement to be used in clinical trials in children with juvenile arthritis…